A method of production of a tissue sealing patch is disclosed. The method comprises applying a vacuum to a heated work surface; applying a solution of a biocompatible polyurethane polymer to the work surface and spreading it over the work surface with a polymer blade; evaporating the solvent; heating the work surface above the softening temperature of the polymer; spreading powdered tissue sealant material over the polymer film; incorporating the tissue sealant material to a depth of 20-60 μm in the film by pressing on a release sheet placed over the powder and polymer film; removing the release sheet from the adhesive patch material; releasing the vacuum; cooling said work surface; and removing the adhesive patch material from said work surface. The biocompatible polymer preferably comprises PEG-caprolactone-lactic acid units connected by urethane linkages, the PEG having a molecular weight of 3000-3500 amu, and a CL:LA:PEG ratio of 34:2:1.

A method of production of a tissue sealing patch is disclosed. The method comprises casting a polymer film from a biocompatible polyethylene glycol-caprolactone-lactide triblock copolymer (PECALA); softening the polymer film; placing a powdered tissue sealant material on a surface of said polymer film; and, pressing said polymer film to at least partially incorporate the sealant material into said surface of said polymer film. In some embodiments of the invention, the polymer film is created by heating and evacuating a work surface; applying a solution of PECALA to said work surface; adjusting a polymer blade to a predetermined height above said work surface; spreading said solution of PECALA over said work surface with said polymer blade; and evaporating said solvent. The PECALA preferably comprises PEG-CL-LA units connected by urethane linkages, PEG having a molecular weight of between 3000 and 3500 amu, and a CL:LA:PEG ratio of 34:2:1.

An implantable medical device, for implantation in a mammal knee joint, comprising an artificial contacting surface adapted to replace at least one contacting surface of the knee joint and to be lubricated when implanted in said joint. The medical device further comprises a reservoir comprising a movable wall portion defining the volume of the reservoir, at least one inlet adapted to receive a lubricating fluid from the reservoir, at least one channel at least partly integrated in said artificial contacting surface, wherein the channel is fluidly connected with said at least one inlet for distributing said lubricating fluid to the surface of said artificial contacting surface. The medical device further comprises an operation device adapted to non-invasively transport said lubricating fluid from said reservoir to said artificial contacting surface, and an implantable injection port for refilling said reservoir, wherein the movable wall portion is moved when the reservoir is refilled, such that the volume of the reservoir is increased.

Compositions are provided herein comprising a coacervate of a polycationic polymer, a polyanionic polymer, and platelet-rich plasma and/or serum, or a fraction or concentrate thereof. The composition is useful in wound healing. Compositions also are provided that comprise a hydrogel comprising TIMP-3; and a complex of a polycationic polymer, a polyanionic polymer, FGF-2 and SDF-1α embedded in the hydrogel, which is useful in treating a myocardial infarction.

An implantable medical device includes a polymer substrate and at least one nanofiber. The polymer substrate includes a surface portion extending into the polymer substrate from a surface of the substrate. The at least one nanofiber includes a first portion and a second portion. The first portion is interpenetrated with the surface portion of the substrate, and mechanically fixed to the substrate. The second portion projects from the surface of the substrate.

An implantable medical device includes a polymer substrate and at least one nanofiber. The polymer substrate includes a surface portion extending into the polymer substrate from a surface of the substrate. The at least one nanofiber includes a first portion and a second portion. The first portion is interpenetrated with the surface portion of the substrate, and mechanically fixed to the substrate. The second portion projects from the surface of the substrate.

Compositions are provided herein comprising a coacervate of a polycationic polymer, a polyanionic polymer, and platelet-rich plasma and/or serum, or a fraction or concentrate thereof. The composition is useful in wound healing. Compositions also are provided that comprise a hydrogel comprising TIMP-3; and a complex of a polycationic polymer, a polyanionic polymer, FGF-2 and SDF-1α embedded in the hydrogel, which is useful in treating a myocardial infarction.

The invention relates to a method for producing a bioartificial and primarily acellular fibrin-based construct, wherein a mixture of cell-free compositions containing fibrinogen and thrombin is applied to a surface and subsequently pressurised. An additional aspect of the invention is directed to such fibrin-based bioartificial acellular constructs obtained according to the invention, with improved biomechanical properties, as well as to the use of same in the field of implantology, cartilage replacement or tissue replacement.

A tissue repair fibrous membrane, preparation method and application thereof, and tissue repair product. The tissue repair fibrous membrane is formed by interweaving fiber filaments having a diameter of 10 nm to 100 μm, and has pore structures formed by interweaving between the fiber filaments. The fiber filaments have concave structures, and have annular convex structures thereon in the radial direction of the filaments.

A method and kit for stopping cerebrospinal fluid (CSF) leaks, comprising penetrating and passing through a dural tissue an applicator to access an interior dural space, injecting from the applicator a fibrinogen-containing solution into said dural space, applying a sealing member containing a fibrinogen polymerizing agent onto an exterior surface of the dural tissue, and forming a polymerized fibrinogen or polymerized fibrin clot by contacting the injected fibrinogen-containing solution and the fibrinogen polymerizing agent.